Abstract:Objective To set up a multiplex real time quantitative PCR method to detect the expression of WT1 and MDR1 gene simultaneously in acute leukemia patient. Methods Total RNA was extracted from k562 cell line and was reverse transcribed to cDNA by the outer primers of WT1 and MDR1 respectively. The cDNA of WT1 and MDR1 were purified and digested by Bam H Ⅰ and Bgl Ⅱ , and then the two fragments were ligated to form the recombinant fragment WT1 + MDR1. The outer forward primer of WT1 and outer reverse primer of MDR1 were used to amplify the recombinant fragment WT1 + MDR1. The PCR product was purified and cloned into pMD18-T vector, and then transferred into E. coli DH-5α. A new kind of WT1-MDRl-contained standard plasmid was obtained from the positive colony. The recombinant plasmid was verified by digestion with restriction enzyme and PCR amplification. A multiplex real time quantitative PCR method was set up with FAM-labeled MDR1 probe and VIC-labeled WT1 probe in one reaction tube. The WT1 and MDR1 gene expression was detected in forty-seven AL patients and thirty-two controls by this method. Seven patients were followed-up to elucidate the relationship between the gene expression levels and clinical prognosis. Results The recombinant plasmid was confirmed by EcoR1 digestion and PCR amplification. The multiplex real time quantitative PCR technique could reach the sensitivity of WT1 and MDR1 gene up to 102 copy/μl. The standard curve slopes were 0. 999 and 0. 998. The WT1 [ 37 000( 163-6 370 000 )copies/μg RNA ] and MDR1 [ 76 200( 179-18 000 000 )copies/μg RNA ]expression levels of AL patients were significantly higher as compared to the controls [ 258( 0-643 ) copies/μg RNA and 333( 0-779 )copies/μg RNA ]( Z= 6. 755,6. 736, P ＜ 0. 01 ). Following up seven patients with similar regimen of chemotherapy, the WT1 and MDR1 expression correlated to the clinical course. Three AL patients with WT1 and MDR1 expression levels (2 170 and 86 900, 1 130 and 5 860, 1 170 and 586 copies/μg RNA )significantly decreased after chemotherapy and kept in the low range ( 370 and 560,138 and 980, 150 and 690 copies/μg RNA ), and had a favorable outcome. Three AL patients with WT1 and MDR1 expression levels ( 1 600 and 11 800, 24 800 and 968, 48 200 and 1 100 000 copies/μg RNA )decreased after initial chemotherapy, but increased significantly afterwards (20 314 and 25 660,184 364 and 31 530, 15 680 and 878 000 copies/μg RNA ),and suffered clinical relapse. One patient with high WT1 and MDR1 expression levels ( from 81 600 and 1 200 000 copies/μg RNA to 124 100 and 7 632 400 copies/μg RNA )showed the persistence of disease. Conclusions A multiplex real time quantitative PCR method to detect WT1 and MDR1 gene simultaneously is constructed successfully. The expression of WT1 and MDR1 may provide useful information for AL patients prognosis.

The Detection of FLT3 Mrna Expression in Patients with Acute Myeloid Leukemia by Real-Time Quantitative Polymerase Chain Reaction Amplification

Establishment of a Rapid and Easy Method for Simultaneous Detection of FLT3-ITD and NPM1 Gene Mutations in Acute Myeloid Leukemia

Clinical Significance of AML/ETO Fusion Gene Mrna in Acute Myelogenous Leukemia.

Fluorescence quantitative PCR detection of TRF1,TRF2 and hRAP1 mRNA expression in AML

Construction of the method for quantitative detection of epidermal growth factor receptor variant Ⅲ by real-time polymerase chain reaction with Taq Man probe and its application

Detection of Translocation ETS Leukemia-Acute Myeloid Leukemia1 Fusion Gene in Acute Lymphoblastic Leukemia Children by Real-Time Fluorescent Quantitative Polymerase Chain Reaction and Its Clinical Significance

Detection of WT1 Gene by Real-Time Quantitative PCR in Childhood Leukemia

The expression of FLT3 gene in different hematotogic maligancy patients and it's clinical significance

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

[Simultaneous Detection of FLT3-ITD and NPM1 Gene Mutations in Acute Myeloid Leukemia by Double PCR].

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia

Rapid detection of FLT3-ITD (exon14-15) gene mutations analysis in acute myelogenous leukemia patients by High Resolution Melting analysis

Applications of Microchip Electrophoresis and Capillary Electrophoresis for Screening FLT3-ITD Gene Mutation in Acute Myeloid Leukemia

[Clinical Significance of Detection of AML1/ETO Fusion Transcripts in Childhood AML Using Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction].

Fluorescence Quantitative Pcr Detection of Flt3 Gene Expression in Leukemias and Its Clinical Implications.

The Feature of TCR-Zeta Chain Expression in Patients with Acute Myeloid Leukemia

Development and Validation of A 3-Plex Rt-Qpcr Assay for the Simultaneous Detection and Quantitation of the Three Pml-Rara Fusion Transcripts in Acute Promyelocytic Leukemia

Fluorescence Quantitative PCR Detection of ABL1 Kinase Region Mutations

Simultaneous detection of WT1 and MDR1 gene expression in acute leukemia patients by a multiplex real time quantitative PCR method

Real-time Quantitative Polymerase Chain Reaction for Dynamic Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia after Treatment

Construction and identification of FLT3-ITD/FIV expression vector and acute myelogenous leukemia cell lines